A. Stabilin-mediated cellular internalization of phosphorothioate-modified Antisense Oligonucleotides (ASOs) Colton M. Miller*, Aaron J. Donner §, Emma.

Slides:



Advertisements
Similar presentations
ATHEROSCLEROSIS THE HDL RECEPTORS A REVIEW AND
Advertisements

INTERPLAY OF POLYMER AND NUCLEIC ACID PROPERTIES ON EFFECTIVENESS OF ANTISENSE OLIGONUCLEOTIDES Antisense oligonucleotides present a potentially powerful.
Vaccines and Antivirals. Clinical Use of Interferon Therefore they have been used in the treatment of cancers of various types. Therefore they have been.
C. HENDRICKS, L. JANSSEN, R. DELCOMBEL, J. DUBAIL, C. DEROANNE, A. COLIGE Laboratory of Connective Tissues Biology, GIGA-Cancer, University of Liège, Tour.
Antisense Phosphorodiamidate Morpholino Oligomer-Peptide Conjugate: Dose-Response in Mice Infected with Escherichia coli Lucas Tilley 1, Patrick Iversen.
Triplex forming oligonucleotides (TFO)
Metabolism Dr. Samah Kotb Lecturer of Biochemistry 2015 Cellular Biochemistry and Metabolism (CLS 331)
1 2 3 M M M Stab1 315-HARE 190-HARE 170 kDa 130 kDa 100 kDa 70 kDa Vinculin Stabilins A. B. C. * ** Fig. S1 * Relative expression Fig. S1.
Adenosine Protects Vascular Barrier Function in Hyperoxic Lung Injury Jonathan Davies 1, Harry Karmouty-Quintana 2, Thuy T. Le 2, Ning-Yuan Chen 2, Tingting.
Small Molecules that Enhance the Pharmacological Effects of Oligonucleotides Melissa Porter 1, Bing Yang 1, Canhong Cao 1, Xin Ming 1, Emily Hull-Ryde.
Volume 50, Issue 3, Pages (March 2009)
Volume 4, Issue 4, Pages (April 2015)
Smita Srivastava, Patricia S. Grace, Joel D. Ernst  Cell Host & Microbe 
Figure 5. ALK2 Is Expressed in All MIS Target Tissues Levels of ALK2, ALK6, and MISRII mRNAs were measured in embryonic mouse urogenital ridges (A) and.
Anura Rambukkana, James L Salzer, Peter D Yurchenco, Elaine I Tuomanen 
Identification of the Major Intestinal Fatty Acid Transport Protein
Expression and cellular localization of human hyaluronidase-2 in articular chondrocytes and cultured cell lines  G. Chow, Ph.D., C.B. Knudson, Ph.D.,
Identification of the receptor scavenging hemopexin-heme complexes
Matrix Metalloproteinase 9 Expression is Coordinately Modulated by the KRE-M9 and 12-O-Tetradecanoyl-Phorbol-13-Acetate Responsive Elements  Takashi Kobayashi,
by Herbert Bosshart, and Ruth F. Jarrett
Volume 19, Issue 2, Pages (February 2017)
Volume 7, Issue 8, Pages (August 2000)
Particle assembly incorporating a VP22–BH3 fusion protein, facilitating intracellular delivery, regulated release, and apoptosis  N.D. Brewis, A. Phelan,
Volume 4, Issue 1, Pages (July 2001)
Volume 22, Issue 5, Pages (May 2012)
Volume 16, Issue 4, Pages (April 1996)
Volume 16, Issue 22, Pages (November 2006)
Gapmer Antisense Oligonucleotides Suppress the Mutant Allele of COL6A3 and Restore Functional Protein in Ullrich Muscular Dystrophy  Elena Marrosu, Pierpaolo.
Polina Iakova, Samir S Awad, Nikolai A Timchenko  Cell 
Volume 21, Issue 12, Pages (December 2013)
Volume 10, Issue 3, Pages (September 2009)
Volume 48, Issue 2, Pages (October 2005)
Molecular Therapy - Nucleic Acids
Volume 25, Issue 1, Pages (January 2017)
Volume 21, Issue 8, Pages (August 2014)
Down-Regulation of IL-4 Gene Transcription and Control of Th2 Cell Differentiation by a Mechanism Involving NFAT1  Alexander Kiani, João P.B Viola, Andrew.
Smita Srivastava, Patricia S. Grace, Joel D. Ernst  Cell Host & Microbe 
Microtubule-Targeted Drugs Inhibit VEGF Receptor-2 Expression by both Transcriptional and Post-Transcriptional Mechanisms  Markus Meissner, Andreas Pinter,
Microglial Cells Internalize Aggregates of the Alzheimer's Disease Amyloid β-Protein Via a Scavenger Receptor  Donata M. Paresce, Richik N. Ghosh, Frederick.
Jungmook Lyu, Vicky Yamamoto, Wange Lu  Developmental Cell 
Volume 7, Issue 8, Pages (August 2000)
Volume 15, Issue 6, Pages (June 2012)
Legionella Reveal Dendritic Cell Functions that Facilitate Selection of Antigens for MHC Class II Presentation  Annie L Neild, Craig R Roy  Immunity 
Volume 19, Issue 7, Pages (July 2012)
Role of the regulatory domain of the EGF-receptor cytoplasmic tail in selective binding of the clathrin-associated complex AP-2  Werner Boll, Andreas.
Volume 23, Issue 12, Pages (December 2015)
Volume 25, Issue 5, Pages (November 2006)
Volume 17, Issue 4, Pages (October 2009)
Volume 18, Issue 4, Pages (April 1997)
Molecular Therapy - Methods & Clinical Development
Modular Three-component Delivery System Facilitates HLA Class I Antigen Presentation and CD8+ T-cell Activation Against Tumors  Benjamin J Umlauf, Chin-Ying.
Molecular Therapy - Nucleic Acids
Amphiregulin Exosomes Increase Cancer Cell Invasion
BMDC-EV attract immune cells in lymph nodes similarly as in the skin.
Volume 17, Issue 5, Pages (November 2002)
Molecular Basis for Target RNA Recognition and Cleavage by Human RISC
Synthetic Oligonucleotides Inhibit CRISPR-Cpf1-Mediated Genome Editing
Jeremy E. Wilusz, Susan M. Freier, David L. Spector  Cell 
Patrick Wigge, Yvonne Vallis, Harvey T. McMahon  Current Biology 
Yuri Oleynikov, Robert H. Singer  Current Biology 
The Membrane-Lytic Peptides K8L9 and Melittin Enter Cancer Cells via Receptor Endocytosis following Subcytotoxic Exposure  Masayuki Kohno, Tomohisa Horibe,
Volume 13, Issue 10, Pages (December 2015)
Toshiyuki Araki, Jeffrey Milbrandt  Neuron 
Volume 55, Issue 2, Pages (February 1999)
Particle assembly incorporating a VP22–BH3 fusion protein, facilitating intracellular delivery, regulated release, and apoptosis  N.D. Brewis, A. Phelan,
Volume 20, Issue 6, Pages (June 2012)
Volume 16, Issue 4, Pages (April 1996)
Identification of the Major Intestinal Fatty Acid Transport Protein
Molecular Therapy - Methods & Clinical Development
Volume 10, Issue 6, Pages (December 2004)
Presentation transcript:

A. Stabilin-mediated cellular internalization of phosphorothioate-modified Antisense Oligonucleotides (ASOs) Colton M. Miller*, Aaron J. Donner §, Emma K. Blank*, Andrew W. Egger*, Brianna M. Keller*, Punit P. Seth §, Edward N. Harris* *University of Nebraska, Dept. of Biochemistry, Lincoln, NE 68588, § Ionis Pharmaceuticals, Inc., Carlsbad, CA The authors don’t have anything to disclose with the presented information. Introduction: Antisense oligonucleotides (ASOs) are short chemically modified oligonucleotides (5-7.4 kDa) that can produce a pharmacological effect by binding to RNA and affecting intermediary metabolism. Over 35 phosphorothioate (PS) ASOs are at various stages of clinical development for use as therapeutic agents and pharmacological tools. Antisense therapy is a progressing area of research, as these small strands of nucleotide oligomers can be produced to silence genes that aggravate chronic disorders or infections. An important distinction for ASOs compared to DNA is the substitution of the phosphodiester (PO) backbone with the PS modification. This sulfur substitution allows for these polar polyanionic molecules to have high stability in biological fluids and selective binding to cell surfaces. Although there is a premium for clinical development of these short chain molecules, the current understanding of the pathways for their ability to traverse plasma membranes remains unresolved. Injected gymnotic ASOs have been shown to accumulate in the liver via the organ’s functional scavenging mechanism in highly endocytically active sinusoidal endothelial cells (SECs) and Kupffer cells (KC) compared to hepatocytes. Our work outlines how a non-DNA binding class of scavenger receptors known as Stabilins binds to, and internalizes these small PS ASOs. Methods: Primary cells from rat and mouse were isolated and cultured with 125 I-ASOs. Stable cell lines expressing Stabilin-1 and two Stabilin-2 isoforms (315-HARE and 190-HARE), were used to analyze binding affinity, endocytosis and degradation of 125 I-ASOs in the cell. Co- localization was also done to analyze trafficking of ASOs once internalized within the cell by use of fluorescent ASO and lysotracker. Results: It was determined that PS ASOs bind with high affinity to the Stabilin class receptors with the majority of internalization performed by clathrin-mediated endocytosis. Binding was determined to be dependent on proper folding of the receptor, along with relying on salt-bridge formation. Once inside the cell via the Stabilin receptors, co-localization analysis showed ASOs being trafficked for degradation in the lysosome. Increased internalization rates of an ASO targeting the non- coding RNA of malat-1, in the Stabilin-expressing cell lines reduced malat-1 expression more efficiently, indicating not all ASOs are trafficked to the lysosome after internalization. Conclusion: Our work shows that ASOs are internalized into the cells of the liver through clathrin-mediated endocytosis. The understanding of the pathway(s) for chemically modified ASO internalization and trafficking with cell surface receptors will aid in future clinical design of ASOs as therapeutic agents. Introduction: Stabilin receptors Introduction: Antisense Oligonucleotides (ASO) Fig. 2: Components of ASOs Table. 1: ASO polymers used in this study. Fig. 3: Half-life and tissue distribution in mice. A) Intravascular injections in mice with 1.0 mg/kg 125 I-ASO resulted in a half-life of 9 min in the blood. B) Approximately 20% of all ASO was contained in the liver. C) Within the liver, over 80% of the ASO was in the non-parenchymal fraction and D) the highest distribution of ASO was in the LSECs. Fig. 4: Stabilin receptor internalize ASOs. A) Cell lysates on 5% SDS-PAGE from HEK Flp-In 293 cells expressing parent pcDNA5 (empty vector (EV)) (lane 1), Stabilin-1 (lane 2), Stabilin-2, 315-HARE (lane 3, black arrowhead), or Stabilin-2, 190-HARE (lane 4, open arrowhead) were probed with anti-V5 to visualize recombinant protein expression and anti-vinculin as load control (black arrow). B) All four cell lines were subject to 0.1  M 125 I-ASO over 9 hrs. C) At least half of the internalization is regulated by clathrin-mediated endocytosis (gray bars) in contrast to untreated controls (black bars). D) A small increase in binding occurs with the 190-HARE cells and not with the other cell lines when compared with EV indicating that Stabilin receptors are primarily involved with endocytosis of ASO from the cell surface. NS = not significantly different from control. * is p= Abstract Results Fig. 5: Binding characteristics of ASO and 190-HARE. A) Purified 190-HARE or BSA was plated in polysorp wells and incubated with increasing concentrations of 125 I-ASO. B) 0.05  M 125 I-ASO was incubated with increasing concentrations of NaCl to disrupt ionic bonding, urea to disrupt hydrogen bonding, or guanidinium chloride to disrupt protein folding. Fig. 6: Endocytosis with competition. All four cell lines were incubated with 0.1  M 125 I-ASO in the presence of 20  M competitor as indicated for up to 90 min. Fig. 7: Competition in both 190-HARE and rat primary LSECs. A) 190-HARE and B) rat LSECs were incubated with 0.1  M 125 I-ASO with 20  M the indicated competitors for 90 min showing similar uptake values. Fig. 8: Stabilin receptors traffick ASO to lysosomes. A) EV and 190- HARE cells were incubated with 0.05  M Cy3-ASO (red) for 1, 3, or 6 hrs and then incubated with 1.0  M Lysotracker (green) for 25 min. and imaged by confocal microscopy. Images were processed with Fiji Coloc-2 software and the colocalization data was quantified in B. Fig. 10: Degradation of ASO in cells. EV, 190-HARE and 315- HARE cells were incubated with 0.1  M 125I-ASO for 2 hrs (pulse), washed with PBS, and incubated in fresh medium for 6 additional hrs (chase). The chase medium was subject to DEAE column chromatography to capture the ASO. Degraded and partially degraded ASO was eluted with 0.4 M NaCl and intact ASO was eluted with 2.0 M NaCl. A) The ratio of degraded to intact ASO was highest in the Stab2 expressing cell lines in contrast to the EV. B) Left: 125 I-ASO was assessed for intrisic degradation in the prepartion indicated that at least 80% was intact (black bars). Mice were injected with 1.0 mg/kg 125 I- ASO and urine was collected over a 2 hr period resulting in the majority of ASO in urine is degraded. Fig. 11: Efficient gene expression knockdown in Stabilin- expressing cells. All four cell lines were incubated with  M ASO against malat-1, a long non-coding RNA, for A) 24 or B) 48 hrs and assessed for malat-1 expression levels by qPCR. Conclusions Liver is a primary site for ASO sequestration from blood. Stabilin-1 and both Stabilin-2 receptors increased internalization of ASOs from the cell surface. ASOs bind Stabilins via ionic bonding ASOs composed of phophorothioate linkages and methoxyethyl modifications have higher affinities for the Stabilins than the morpholinos or phosphodiester ASOs. Internalization by the Stabilin receptors increases lysosome delivery which is a dead-end for ASOs, but receptor internalization also enhances gene knock- down. B.A. B. A. B. C.D. A.B. C.D. Funding Sources : National Institutes of Health – NHLBI R01 5R01HL University of Nebraska Undergraduate Creative Activities and Research Experience (UCARE). Contact information of main authors: Edward Harris, Univ. of Nebraska, Punit Seth, Isis Pharmaceuticals, There are no financial disclosers to report associated with this work Fig. 1: The Stabilin receptors. Stab1 and Stab2 are expressed in endothelium of liver, lymph node, spleen and bone marrow. Both receptors are comprised of the same domain organization, although Stab1 does not have a functional LINK domain and cannot be categorized as a hyalectin. Both receptors bind to heparin, GDF-15, phosphatidylserine, advanced glycation end-products (AGE), and modified LDL. Individually, Stab1 binds to lactogen and SPARC and Stab2 binds with HA, CS, and collagen pro-peptides. Neither receptor binds natural DNA or RNA with phosphodiester backbones. Both receptors undergo proteolytic cleavage/maturation with Stab1 expressed as isomers of nearly the same size in a 1:1 ratio and Stab2 expressed as 315- and 190-kDa receptors in a 5:1 to 2:1 ratio depending on the tissue. = EGF domain, = Fas-1 domain, = transmembrane domain, = Link domain A.B. C.D. Fig. 9: Endocytosis with Drug Inhibitors. Endocytosis of 0.1 µM 125I-ASO in EV (A), Stabilin-1 (B), 315-HARE (C), and 190-HARE (D) cell lines at one time point (90 mins) as either untreated control (black bars) or with drug/conditions (grey bars) that inhibit clathrin-mediated endocytosis.Dimethyl sulfoxide solvent control, P µM PitStop2, Dy-300 µM-Dynasore, Su-0.4 M sucrose.